Gilead Sciences, Inc.
NASDAQGilead Sciences reports Q1 2026 results today against a backdrop of broad analyst conviction — but a stock that has quietly drifted lower and a short interest position that has been building steadily through April. The Street is notably bullish heading into the print. Morgan Stanley lifted its target to $175 earlier this month, maintaining Overweight, while Citigroup raised to $165…
Snapshot as of 7 May 2026
A new long-form analysis for GILD this week — anomalies vs the company's own history, peer comparisons, news context, and the full data picture. Premium subscribers only.
Read on ORTEX →Sign up for premiumGilead Sciences reports Q1 2026 results today against a backdrop of broad analyst conviction — but a stock that has quietly drifted lower and a short interest position that has been building steadily through April. The…
Gilead Sciences walks into its Q1 2026 results — scheduled for after the close on April 30 — with a notable tension: short interest has risen sharply over the past month, yet the Street remains firmly bullish and a…
Short sellers have largely abandoned GILD ahead of today's earnings. Just 1.73% of the float is sold short, up slightly from March lows but still among the lowest in large-cap biotech. Short interest stands at 21.5…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for GILD — free to start on ORTEX.
Sign up for free →Open GILD on ORTEX